Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma

Clinical trial NCT03400592 · UNKNOWN

Trial details

NCT number: NCT03400592
Sponsor: Peking University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Stomach Neoplasms

Start date: 2015-06-01
Primary completion: 2018-06-01
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.